The Donald Trump administration is unveiling a government website that connects people to buy prescription drugs directly from pharmaceutical companies. The government says this will allow citizens to purchase medicines at lower prices, but some warn that, depending on the case, the expense burden could actually grow.
On the 5th (local time), President Trump held an event at the White House to introduce the launch of TrumpRx. Earlier, White House Spokesperson Karoline Leavitt said President Trump would officially unveil the TrumpRx platform at the evening event with Mehmet Oz, head of the Centers for Medicare & Medicaid Services (CMS), and Joe Gebbia, chief design officer (CDO) of the National Design Studio.
At the event, President Trump said, "Dozens of the most commonly used prescription drugs will be offered to all consumers at dramatically discounted prices starting tonight." He has pressured major pharmaceutical companies with a tariff to bring down prices on popular medicines, and this is seen as emphasizing that those efforts have in fact led to lower drug prices.
TrumpRx does not appear to be a platform where the government directly distributes or sells medicines. Instead, when consumers enter the medications they are taking into the search bar, it functions more as a guidance gateway that consolidations to the direct-purchase site of the pharmaceutical company that makes the product. Actual payment is made on the pharmaceutical company's website, and as before, a doctor's prescription is required to buy.
Currently, the TrumpRx site features obesity treatments Wegovy and zepbound, and the ovulation induction drug Gonal-F Pen, among others. No separate membership sign-up is required, and when you search by drug name or condition in the search bar, related prescription drugs are retrieved at the lowest price. According to the site, more medicines are expected to be added later.
However, because TrumpRx applies discounted prices only to cash-paying patients, some analysts say it will offer little help to people with insurance. Since most of the drugs expected to be added to TrumpRx are covered by private insurance, consumers who had been paying only low out-of-pocket costs may instead have to pay additional expense.
On the other hand, for medicines with limited insurance coverage, such as obesity and infertility treatments, the platform is expected to offer significant advantages. These drugs have already seen a sharp rise in the use of direct-purchase channels from drugmakers, and Eli Lilly released that about 1 million patients flocked over two years to its direct-purchase site selling the obesity treatment zepbound. Novo Nordisk also said that 30% of Wegovy patients are buying the drug out of pocket rather than through insurance.
Experts stress that insured consumers should compare their out-of-pocket share with TrumpRx prices. Rachel Sachs, a Washington University law professor, said, "Even if it looks like a good deal on the surface, some patients could end up in a worse financial position."